Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443699 | 0.88 | MAOB (0.55) | KDM4EDRD2DRD3SIGMAR1MAOB | |
| SCHEMBL4763329 | 0.86 | MAOB (0.57) | KDM4EDRD2DRD3SIGMAR1MAOB | |
| SCHEMBL1474106 | 0.86 | PIM1 (0.52) | KDM4EHRH3ACHEDRD2DRD3 | |
| SCHEMBL3056169 | 0.85 | KDM4E (0.54) | KDM4EDRD2DRD3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7533535 | 0.84 | KDM4E (0.53) | KDM4EDRD2DRD3ALDH1A1KMT2A | |
| SCHEMBL1474145 | 0.83 | PIM1 (0.49) | KDM4EHRH3DRD2DRD3ALDH1A1 | |
| SCHEMBL5105731 | 0.81 | CYP1A2 (0.52) | KDM4EBCHEACHEDRD2DRD3 | |
| SCHEMBL4765626 | 0.81 | DRD2 (0.52) | DRD2DRD3MAOB | |
| SCHEMBL445130 | 0.78 | KDM4E (0.55) | KDM4EBCHEACHEDRD2DRD3 | |
| SCHEMBL15623105 | 0.78 | KDM4E (0.58) | KDM4EBCHEACHEDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | KDM4E 2528/4885HRH3 89/4885BCHE 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.